Clinical Trial Update: Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ropeginterferon alfa-2b (P1101) in interferon treatment-naive subjects with hepatitis C virus genotype 2; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ropeginterferon alfa-2b (P1101) (ropeginterferon alfa-2b)

Snippet

Sponsor: PharmaEssentia | Conditions: Chronic Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED